Metrion Biosciences plots global growth by doubling its space with new Granta Park headquarters
Metrion Biosciences has moved into new headquarters on Granta Park, which more than doubles its laboratory space.
The specialist ion channel contract research and drug discovery company said the new custom-designed lab and office premises will enable it to expand its services and cell lines significantly.
The 12,000 sq ft headquarters have been designed to support the addition of Good Laboratory Practice (GLP) compliant cardiac safety services and expanded cell biology facilities.
Chief executive Dr Andrew Southan said: “Our new headquarters has been specifically designed to support Metrion’s ambitious business plan for global growth, with a particular focus on the USA in 2022.
“Following the recent appointment of Nick Foster as chief commercial officer, the additional space will also allow for further growth of Metrion’s team of expert laboratory scientists.
“Metrion continues to build its reputation as a leading provider of drug discovery research services for ion channel targets across multiple therapeutic areas and I look forward to working with the team during this next phase of growth for our company.”
The expansion comes following sustained growth for Metrion, which has increased its headcount by 50 per cent over the past three years while based on Granta Park site and continues to recruit.
The company secured £2.7million in April in new equity financing, including £2.25m from lead investor Gresham House Ventures, to fund the expansion.
The new labs provide dedicated laboratory space for the introduction of 384-well format automated electrophysiology and enhanced liquid handling.
Sign up for our weekly newsletter and stay up to date with Cambridge business